FDA Patient Listening Session "Drug Development in Molecular Subsets of Non-Small Cell Lung Cancer"

KRAS Kickers had the privilege of participating in the insightful FDA Listening Session for Non-Small Cell Lung Cancer (NSCLC), where crucial topics such as lung cancer symptoms, biomarker testing, clinical trials, and advancements in KRAS research were explored. This session served as an empowering platform for patients, caregivers, healthcare professionals, and researchers to deepen their understanding and engage in meaningful discussions surrounding NSCLC.

During the session, the focus was on raising awareness about lung cancer symptoms, encompassing both small cell lung cancer and non-small cell lung cancer, emphasizing the importance of early detection and diagnosis. The significance of biomarker testing in tailoring treatment decisions and delivering personalized care was highlighted, with special attention given to key biomarkers such as KRAS mutations, including KRAS G12C and KRAS G12D.